ENHERTU lands 10th FDA breakthrough status in early breast cancer milestone
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have secured their tenth Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration for ENHERTU, marking a pivotal expansion into the early-stage treatment of breast cancer.






-640x358.jpg&w=1200&q=75)



-640x358.jpg&w=1200&q=75)